KALA - Kala Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

KALA is currently covered by 3 analysts with an average price target of $282.24. This is a potential upside of $273.9 (3284.17%) from yesterday's end of day stock price of $8.34.

Kala Pharmaceuticals's activity chart (see below) currently has 16 price targets and 47 ratings on display. The stock rating distribution of KALA is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 5.06% with an average time for these price targets to be met of 26.63 days.

Highest price target for KALA is $15, Lowest price target is $12, average price target is $14.

Most recent stock forecast was given by ANDREAS ARGYRIDES from OPPENHEIMER on 02-Jun-2025. First documented stock forecast 14-Aug-2017.

Currently out of the existing stock ratings of KALA, 12 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$15

$6.68 (80.29%)

$22

2 months 18 days ago
(02-Jun-2025)

0/3 (0%)

$11.48 (326.14%)

Buy

$12

$3.68 (44.23%)

$15

2 months 28 days ago
(23-May-2025)

1/14 (7.14%)

$7.96 (197.03%)

65

Buy

$15

$6.68 (80.29%)

$15

1 years 1 days ago
(19-Aug-2024)

0/3 (0%)

$8.72 (138.85%)

Buy

3 years 5 days ago
(15-Aug-2022)

0/2 (0%)

$390 (108.33%)

Sell

3 years 4 months 21 days ago
(30-Mar-2022)

0/2 (0%)

$815 (87.17%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is KALA (Kala Pharmaceuticals) average time for price targets to be met?

On average it took 26.63 days on average for the stock forecasts to be realized with a an average price target met ratio 5.06

Which analyst has the current highest performing score on KALA (Kala Pharmaceuticals) with a proven track record?

FRANCOIS BRISEBOIS

Which analyst has the current lower performing score on KALA (Kala Pharmaceuticals) with a proven track record?

RAGHURAM SELVARAJU

Which analyst has the most public recommendations on KALA (Kala Pharmaceuticals)?

Francois Brisebois works at OPPENHEIMER and has 3 price targets and 2 ratings on KALA

Which analyst is the currently most bullish on KALA (Kala Pharmaceuticals)?

Tazeen Ahmad with highest potential upside - $791.1

Which analyst is the currently most reserved on KALA (Kala Pharmaceuticals)?

Chris Schott with lowest potential downside - -$0

Kala Pharmaceuticals in the News

KALA BIO Non-GAAP EPS of -$1.71

* KALA BIO press release [https://seekingalpha.com/pr/20194841-kala-bio-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:KALA [https://seekingalpha.com/symbol/KALA]): Q2 Non-GAAP EPS of -$1.71. * Cash resources of $31.9 million as of June 30, 2025, expected to fund operations into 1Q 2026 MORE ON KALA BIO * Seeking Alpha’s Quant Rating on KALA BIO [https://seekingalpha.com/symbol/KALA/ratings/quant-ratings] * Historical earnings data for KALA BIO [https://seekingalpha.com/symbol/KALA/earnings] * Financial information...

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

— Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 — — Cash resources of $31.9 million as of June 30, 2025, expected to fund operations into 1Q 2026 — ARLINGTON, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) — KALA BIO,...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?